AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

We recently published a list of 10 Magnificent Dividend Growth Stocks to Invest In. In this article, we are going to take a ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...

Moderna, AbbVie, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares in companies that focus on developing and ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...

AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...

AbbVie Inc. ( NYSE: ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R. Stewart - Executive ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...